Strategies to enhance tumor immunogenicity may expand the role of immunotherapy beyond the mismatch repair-deficient subtype. In this pilot study, biopsies were performed at baseline and after four cycles of FOLFOX in eight patients receiving neoadjuvant chemotherapy for stage II/III locally advanced rectal cancer. Immunostaining was performed for T cell subsets (CD3+, CD8+, CD45RO+); macrophages (CD163+); T regulatory cells (FOXP3+); and expression of MHC class I, PD-1 and PD-L1.
Introduction
Immunotherapies have become routine in treatment of various cancers, such as melanoma, where checkpoint blockade of CTLA-4 and PD-1 T-cell inhibitory molecules helps lengthen progression-free survival and overall survival. 1 T-cell regulatory (Treg) receptor PD-1 and its ligand PD-L1 are expressed in most cancers, 2 and together they can dampen the antitumor immune response.
Tumors thought to be susceptible to anti-PD-1 include those with high mutational load and neoantigen burden 3 or with evidence of an immune-active tumor microenvironment (CD3/CD8+
infiltrates and MHC class I expression). 4, 5 Intratumoral PD-1/PD-L1 expression and presence of T cells within the tumor microenvironment are thought to represent the most useful indicator that anti-PD-1 therapy may be effective.
To date, the role of immunotherapy in colorectal cancer (CRC) has been limited to the mismatch repair-deficient (dMMR) subtype. dMMR tumors are strongly immunogenic, with high numbers of tumor-infiltrating lymphocytes thought to be responding to neoantigens brought about by the high mutational burden. 6 Compared with mismatch repair-proficient (pMMR) CRC, dMMR tumors also express higher levels PD-1/PD-L1. 7, 8 Phase II trials have shown that anti-PD-1/PD-L1 agents help lengthen progression-free and overall survival in patients with stage IV dMMR CRC. 9, 10 However, since dMMR tumors account for only 25%, 12% and 4% of stage II, III and IV CRCs, respectively, immunotherapy is a treatment option in only a small subset of CRCs. Observational data suggest that RT enhances T cell infiltration in locally advanced rectal cancer, and preclinical models suggest that cytotoxic chemotherapy may have similar effects. [14] [15] [16] [17] [18] However, the effect of cytotoxic chemotherapy on intratumoral immune responses in patients with CRC has not previously been studied. In this prospective pilot study, we investigated whether conventional cytotoxic chemotherapy can induce immune priming in pMMR locally advanced rectal cancer.
Results
Matched biopsies taken before and after four cycles of induction FOLFOX chemotherapy (folinic acid, fluorouracil and oxaliplatin) were collected in eight patients: six men and two women, ages 33-78 years. The clinical and pathological characteristics of the cohort are listed in The data on pre-and posttreatment tumor immune responses are shown in Table 2 and Figure 1 .
Pretreatment patterns of immune infiltrates were mixed and did not appear to correlate with responses to treatment. CD3+ and CD8+ infiltrates increased in five patients, CD45RO+ infiltrates increased in four patients, and CD163+ cells increased in four patients. The MHC-I histoscore increased in five patients, the PD-1 score increased in seven patients, and the PD-L1 score increased in four patients. FOXP3+ infiltrates increased in two patients, decreased in two other patients and remained unchanged in three patients (pretreatment FOXP3+ data was not available for one of the eight patients). The two patients with increases in FOXP3+ cells had poor responses to treatment, whereas the patient with the greatest reduction in FOXP3+ cells had a complete clinical response (Fig. 2) . The patient with a complete response had a much higher increase in MHC-I expression within the tumor than the other patients.
Discussion
The findings of our pilot study suggest that FOLFOX chemotherapy is capable of inducing changes in the immune contexture within the tumor microenvironment, such as increases in T cells (CD3+, CD8+ and CD45RO+) and in MHC-I and PD-1 expression. These changes are similar to those observed in preclinical models after chemoradiotherapy (CRT) secondary to immunogenic cell death with antigen release, increased MHC-I and cross-presentation to T cells. [15] [16] [17] [18] [19] In rectal cancer patients treated with CRT, higher numbers of CD4+/CD8+ cells in resected specimens than in pretreatment biopsies have been reported. 14, 20 CRT also induces systemic immune changes, including reductions in circulating Tregs and myeloid-derived suppressor cells. 21 This immunomodulation may account for the reported abscopal effects on distant metastases after RT to the primary tumor, potentially mediated by cross-priming of T cells following tumor cell death. 12, 18, 19 Our results are consistent with previous reports of association between changes in Tregs and treatment response. We observed that tumors in which FOXP3+ Tregs increased had a poor treatment response. The role of Tregs in CRC is not clear, but they are known to harbor immunosuppressive activity, dampening T cell responses. 22 Low numbers of FOXP3+ Tregs in posttreatment resection specimens have been reported to be associated with greater treatment response after CRT. 23 No strong relationship between pretreatment Tregs and treatment response has been observed, suggesting that the type of immune response generated by RT is more important. In summary, the results of our pilot study indicate that FOLFOX chemotherapy in patients with locally advanced rectal cancer was associated with increases in T cell infiltrates, MHC-I expression and PD-1 expression. It is likely that the immunogenicity generated in response to chemotherapy plays a role in treatment response, and evidence of this role may be more apparent in a larger study.
Our findings suggest that neoadjuvant chemotherapy can potentially be utilized to prime immune responses prior to immunomodulatory treatments. These observations provide support for ongoing work investigating the role of immune stimulation by conventional treatments in rectal cancer and for future trials aimed at evaluating combinations of chemotherapy, RT, and immunotherapy.
Patients and Methods

Patients
The study population consisted of nonconsecutive patients seen over a 4-month period with locally advanced rectal cancer clinically staged cT3/4 or N+ (American Joint Committee on Cancer stage II and III) who received neoadjuvant therapy prior to planned rectal resection. As per National
Comprehensive Cancer Network guidelines, the patients received eight cycles of induction FOLFOX prior to CRT. 25 With approval from the institutional review board, we prospectively evaluated the immune contexture of tumor biopsies taken at baseline and after four cycles of FOLFOX chemotherapy. All patients were considered to have pMMR tumors based on pretreatment biopsy immunohistochemistry (no loss of MLH1, PMS2, MSH2 or MSH6 protein expression).
Samples
Immunohistochemistry was performed on matched samples (biopsy at initial diagnosis and after four cycles of FOLFOX) to grade infiltrates of T cells (CD3+, CD8+, CD45RO+), Tregs (FOXP3+) and macrophages (CD163+) (Fig. 3) . We also evaluated MHC-I (as a measure of antigen presentation)
and 
Immune response
Immune cells expressing CD3+, CD8+, CD45RO+, FOXP3+ or CD163+ were quantified in biopsy specimens using a cell counting approach. For each specimen, three high-power fields containing both tumor stroma and epithelium were selected at random. Cell counts were averaged over the three fields. MHC-I expression was assigned a modified histoscore obtained by multiplying the percentage of cells expressing MHC-I by the intensity of staining, which was graded on a scale of 0 to 3. Histoscore values therefore ranged from 0 to 300. PD-1 and PD-L1 were assessed using a previously described method. 26 Briefly, tumor cells staining for PD-L1 and tumor-infiltrating lymphocytes expressing PD-1 were graded on a scale from 0 to 2 (0, no staining; 1+, faint or weak staining; 2+, moderate or strong staining). Increases or decreases of >25% in absolute cell counts or antibody staining intensity, in addition to any point change in the PD-1/PD-L1 scores (0-2) in posttreatment samples, were categorized as changes in the immune response. C.R. scored all the slides, with dual scoring for three patients by J.S. to ensure consistency. A reduction of <50% in tumor bulk was categorized as poor response, and a reduction of 50-99% was categorized as a good but incomplete response.
Staging and clinical response
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